## **Product** Data Sheet

## HDAC-IN-27

Cat. No.:HY-142690CAS No.:2763368-89-2Molecular Formula: $C_{20}H_{22}N_4O_2$ Molecular Weight:350.41

Target: HDAC

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

NH N N N

## **BIOLOGICAL ACTIVITY**

Description	HDAC-IN-27 (Compound 11h) is a potent, selective and orally active HDAC Class I inhibitor, with IC $_{50}$ values ranging from 0.43 nM to 3.01 nM for HDAC1-3. HDAC-IN-27 shows anti-acute myeloid leukemia (AML) activity <sup>[1]</sup> .
In Vitro	In wt-p53 MV4-11 cells, HDAC-IN-27 (11h) leads to pro-caspase-3 cleavage, apparent apoptotic cell death, and accumulation of sub-G1 cell population while inducing G2/M arrest in HL60 cells with no evidence of apoptosis <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Jiang Y, et al. Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo. J Med Chem. 2022;65(1):285-302.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA